HCPLive Network

Hepatitis C

In the era of rapidly improving cure rates for hepatitis C infection, has the importance of staging as part of treatment diminished?
A new clinical trial in children is set to begin that will test the blockbuster hepatitis C drug Sovaldi in combination with ribavirin as part of an all-oral regimen.
The US FDA last week approved the combo drug (trade name: Harvoni) for use in the US.
In treatment-naive patients with genotype 4 HCV, treatment with daclatasvir in combination with peginterferon alfa/ribavirin resulted in higher SVR12 rates than treatment with peginterferon alfa/ribavirin alone.
Increased prevalence of hepatitis C infection among the nation’s young is the subject of a new federally funded study underway in New Mexico.
A generic version of Gilead Science’s hepatitis C drug Sovaldi will be produced in India and sold there and in other poorer countries at what is likely to be a fraction of what it costs in the United States.
Hepatitis C Latest News
Hepatitis C Clinical Trials